Oncobiologics (OTLK)
(Delayed Data from NSDQ)
$8.01 USD
+0.06 (0.75%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $8.00 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Oncobiologics, Inc falls in the month of September.
All items in Millions except EPS data.
9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 8 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 53 | 63 | 52 | 37 | 44 |
Income After Depreciation & Amortization | -53 | -63 | -52 | -37 | -36 |
Non-Operating Income | -4 | -1 | -1 | 0 | 2 |
Interest Expense | 2 | 1 | 1 | 2 | 3 |
Pretax Income | -59 | -66 | -53 | -39 | -38 |
Income Taxes | 0 | 0 | 0 | -3 | -3 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -59 | -66 | -53 | -35 | -35 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -59 | -66 | -53 | -35 | -35 |
Depreciation Footnote | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -53 | -63 | -51 | -36 | -33 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 1 | 3 |
Income After Depreciation & Amortization | -53 | -63 | -52 | -37 | -36 |
Earnings Per Share Data | 9/30/23 | 9/30/22 | 9/30/21 | 9/30/20 | 9/30/19 |
---|---|---|---|---|---|
Average Shares | 12.51 | NA | 7.63 | 3.63 | 0.91 |
Diluted EPS Before Non-Recurring Items | -4.80 | NA | -7.00 | -13.40 | -39.60 |
Diluted Net EPS (GAAP) | -4.80 | -6.20 | -7.00 | -13.40 | -39.60 |
Fiscal Year end for Oncobiologics, Inc falls in the month of September.
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 19.56 | 18.94 | 10.32 | 12.45 | 18.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | -19.56 | -18.94 | -10.32 | -12.45 | -18.14 |
Non-Operating Income | 63.97 | -92.26 | -1.04 | -0.84 | -2.93 |
Interest Expense | 0.00 | 3.08 | -0.19 | -0.31 | -0.40 |
Pretax Income | 44.41 | -114.29 | -11.18 | -12.99 | -20.68 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 44.41 | -114.29 | -11.18 | -12.99 | -20.68 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 44.41 | -114.29 | -11.18 | -12.99 | -20.68 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 25.48 | 14.27 | 13.01 | 12.51 | 12.84 |
Diluted EPS Before Non-Recurring Items | -0.83 | -1.55 | -0.80 | -1.00 | -1.60 |
Diluted Net EPS (GAAP) | -0.89 | -8.01 | -0.80 | -1.00 | -1.60 |